These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8511441)

  • 1. Two-stage tests for studying monotherapy and combination therapy in two-by-two factorial trials.
    Hung HM
    Stat Med; 1993 Apr; 12(7):645-60. PubMed ID: 8511441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size adaptation in fixed-dose combination drug trial.
    James Hung HM; Wang SJ
    J Biopharm Stat; 2012; 22(4):679-86. PubMed ID: 22651108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing for the existence of a desirable dose combination.
    Hung HM; Chi GY; Lipicky RJ
    Biometrics; 1993 Mar; 49(1):85-94. PubMed ID: 8513112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of factorial survival experiments.
    Slud EV
    Biometrics; 1994 Mar; 50(1):25-38. PubMed ID: 8086609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bootstrap and second-order tests of risk difference.
    Lloyd CJ
    Biometrics; 2010 Sep; 66(3):975-82. PubMed ID: 19912176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of several testing strategies for combination drug efficacy trials based on the closure principle.
    Soulakova JN
    Stat Med; 2009 Jan; 28(2):260-73. PubMed ID: 18991315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global tests for combination drug studies in factorial trials.
    Hung HM
    Stat Med; 1996 Feb; 15(3):233-47. PubMed ID: 8643882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factorial designs in clinical trials: the effects of non-compliance and subadditivity.
    Brittain E; Wittes J
    Stat Med; 1989 Feb; 8(2):161-71. PubMed ID: 2704898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The likelihood ratio for comparing means when a portion of the subjects fail to respond.
    Johnson WD; Kelly AM
    J Biopharm Stat; 1993 Mar; 3(1):73-84. PubMed ID: 8485537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling clinical trials in heterogeneous samples.
    Liu W; Zhao W; Shaffer ML; Icitovic N; Chase GA
    Stat Med; 2005 Sep; 24(18):2765-75. PubMed ID: 16007572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A common misapplication of statistical inference: Nuisance control with null-hypothesis significance tests.
    Sassenhagen J; Alday PM
    Brain Lang; 2016 Nov; 162():42-45. PubMed ID: 27543688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of gatekeeping and other testing methods for identifying superior drug combinations in bifactorial designs with isotonic parameters.
    Soulakova JN
    J Biopharm Stat; 2011 Jul; 21(4):635-49. PubMed ID: 21516561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample Size Calculation: Inaccurate A Priori Assumptions for Nuisance Parameters Can Greatly Affect the Power of a Randomized Controlled Trial.
    Tavernier E; Giraudeau B
    PLoS One; 2015; 10(7):e0132578. PubMed ID: 26173007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
    Ramiro S; Radner H; van der Heijde D; van Tubergen A; Buchbinder R; Aletaha D; Landewé RB
    Cochrane Database Syst Rev; 2011 Oct; (10):CD008886. PubMed ID: 21975788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Properties of multiple intersection-union tests for multiple endpoints in combination therapy trials.
    Westfall PH; Ho SY; Prillaman BA
    J Biopharm Stat; 2001; 11(3):125-38. PubMed ID: 11725927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal conditional error functions for the control of conditional power.
    Brannath W; Bauer P
    Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conditional and unconditional confidence intervals following a group sequential test.
    Fan X; DeMets DL
    J Biopharm Stat; 2006; 16(1):107-22. PubMed ID: 16440840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size re-estimation incorporating prior information on a nuisance parameter.
    Mütze T; Schmidli H; Friede T
    Pharm Stat; 2018 Mar; 17(2):126-143. PubMed ID: 29181869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-stage sample size re-estimation based on a nuisance parameter: a review.
    Proschan MA
    J Biopharm Stat; 2005; 15(4):559-74. PubMed ID: 16022163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resampling in multiple-dose factorial designs.
    Frommolt P; Hellmich M
    Biom J; 2009 Dec; 51(6):915-31. PubMed ID: 20029896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.